All Articles

Sirion's top-tier IRAP security clearance in Australia is more than compliance; it's a strategic key to a lucrative market and a new benchmark for trust in AI.

Tyson Foods' $1B bond offering isn't just about money. It's a calculated move to reshape its debt, signal market confidence, and fuel its global mission.

MiTAC's new California facility is more than a ribbon-cutting; it's a strategic shift in the AI arms race, localizing the complex hardware that powers our digital world.

Gencor Industries posted a stellar quarter with an 85% jump in operating income, fueled by a record backlog. But is this just a cyclical peak?

ERAM Holdings taps former government talent chief Alok Kumar to lead a major tech-driven expansion in India's human capital market, a strategic move with global impact.

With six straight J.D. Power wins and stellar local reviews, Renewal by Andersen isn't just selling windows. It's selling a business model.

LSBF and SAFRA's new bond-free sponsorships are more than a gift; they are a strategic investment in national talent and a new model for corporate-community partnership.

Security National Financial boosts profits despite falling revenue, revealing a masterclass in operational efficiency and a long-term strategy that defies convention.

A new integration embeds anti-money laundering checks into law firm workflows, answering intense regulatory pressure with a new model for efficiency.

Draganfly posts 26% revenue growth and secures major defense contracts, but a widening comprehensive loss reveals the high cost of its aggressive expansion strategy.

Ealixir's Q2 results reveal a narrowing loss and revenue jump, driven by its new AI engine EALUMINATE and a strategic, scalable move into Italian media.

As Enterprise Products meets investors, it's not just about record profits. It's a dialogue on trust, transition, and the future of America's energy backbone.

As Johnson & Johnson prepares for a key investor conference, its strategy hinges on a potent mix of new drugs, robotic surgery, and a leaner focus.

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

Amplify Energy touts a major profit swing and a new stock buyback, but a look under the hood reveals a complex picture of derivative gains and real-world challenges.

As KNOT Offshore Partners prepares its Q2 earnings report, the market watches closely. Brazil's oil surge provides a powerful tailwind amid a buyout offer.

Amid Q2 losses, Proficient Auto Logistics acquires Hansen & Adkins, betting big on consolidation to navigate an auto haul industry facing an 'inflection point'.

FutureFuel's stunning $25.6M profit swing reveals a blueprint for resilience, powered by regulatory tailwinds in biofuels and reshoring in chemicals.

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.